Careers  |  Sign In  |  Register

Exploring the Data for AML Treated With Magrolimab and Azacitidine

Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial using combination magrolimab and azacitidine for older patients with acute myeloid leukemia (AML). Compared to the standard of care using azacitidine and venetoclax, the phase 1 trial shows higher complete response rates and overall response rates for the magrolimab plus azacitidine cohort.

Click here to learn more.